Celesio UK extends partnership with Barts Health NHS Trust
Celesio UK, which includes LloydsPharmacy, is working in partnership with Barts Health NHS Trust to provide additional outpatient dispensary services at Newham University and Whipps Cross hospitals. This means LloydsPharmacy now operates all four outpatient pharmacies within Barts Health NHS Trust.
The LloydsPharmacy at Newham University Hospital officially opened in February 2018 at a special event which was attended by representatives from Barts Health and Celesio UK.
Andy Burton, director of community services at Celesio UK says: “The outsourcing of outpatient dispensing has proved to be a successful model, not just for Barts Health, but for many Trusts across the UK. Our partnership has demonstrated an enhanced service for outpatients, as well as staff and visitors, by reducing waiting times for prescriptions and providing a range of associated services such as over the counter medicines.
“Crucially, though, it has released clinical capacity for the Trust resulting in efficiencies for the NHS. The hospital’s pharmacy team are able to spend more time on the wards helping inpatients and clinical staff and reduce waiting time for medicines when patients are being discharged. We’re delighted to have won this contract and look forward to extending the benefits of the model to new sites.”
The additional site at Whipps Cross Hospital will open officially in March. LloydsPharmacy has also provided outpatient dispensary services to St Bartholomew’s and The Royal London Hospitals for the last two years. Patients on wards are getting prescriptions faster meaning that they can go home sooner, and outpatients have improved access to over the counter medicines.
Obafemi Shokoya, Chief Pharmacist at Barts Health NHS Trust, says: “The provision of a high quality and efficient pharmacy service for all patients is integral to our work at our hospitals and our trust values. Working in partnership with LloydsPharmacy allows us to provide excellent direct clinical pharmacy care to patients on wards and in specialist areas, whilst ensuring the continued provision of a first-rate dedicated pharmacy service to our outpatients.”
LloydsPharmacy became the first community provider of commissioned outpatient services for the NHS in 2009. They now have over 50 contracts with Trusts to provide outpatient dispensing (OPD) services.
Note to editors
Celesio UK is a leading provider of integrated healthcare services to the NHS specialising in medicines, pharmaceutical care and primary care patient services.
With almost 25,000 employees, more than 1,750 community pharmacies, a UK-wide logistics network and dispensing in excess of 150 million items a year, Celesio UK works in partnership with the NHS, community pharmacies and medicines manufacturers to help UK citizens live longer, healthier and more positive lives. Celesio UK provides customers, the NHS and patients with high levels of service, value, efficiency and innovation.
Celesio UK is part of McKesson Europe and comprises LloydsPharmacy, AAH Pharmaceuticals, LloydsPharmacy Clinical Homecare, Masta, Online Doctor and Betterlife.
McKesson Europe is a leading international wholesale and retail company and provider of logistics and services to the pharmaceutical and healthcare sector. The proactive and preventive approach ensures that patients receive the products and support that they require for optimum care.
With strong brands and about 39,000 employees, the group is active in 13 European countries (thereof with own operations in ten countries; additionally McKesson Europe manages operations in three countries and participates in one country in a joint venture). Every day, the company serves over 2 million customers – at more than 2,100 pharmacies of its own, at about 300 managed pharmacies and at over 5,700 participants in the brand partnership schemes. With 110 own and seven managed wholesale branches in Europe, McKesson Europe supplies more than 55,000 pharmacies and hospitals every day with up to 130,000 pharmaceutical products.
McKesson Corporation, San Francisco, USA, is the majority shareholder in McKesson Europe. McKesson is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology.